Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mateon Provides Corporate Update and Reports Second Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the
View HTML
Toggle Summary Mateon Therapeutics Completes Enrollment in Phase 2 Portion of FOCUS Study of CA4P for Platinum-Resistant Ovarian Cancer
Recruitment rate significantly increased following initial positive interim analysis Interim data read-outs expected in August (40 patients), September (60 patients) and November (80 patients) SOUTH SAN FRANCISCO, Calif. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc.
View HTML
Toggle Summary Mateon Therapeutics Announces Positive Initial Data from Fifth Cohort of Phase 1b Study of OXi4503 in Relapsed/Refractory AML
Two patients of four (50%) achieved a complete remission No dose-limiting toxicities observed SOUTH SAN FRANCISCO, Calif. , July 31, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan
View HTML
Toggle Summary Mateon Therapeutics Announces New Interim Preclinical Data on CA4P in Combination with Checkpoint Inhibitors
CA4P in combination with anti-CTLA-4 antibodies resulted in 77% reduction in tumor size compared to anti-CTLA-4 antibodies alone and 89% reduction compared to control Survival benefit observed for animals receiving combination therapy SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary Mateon Therapeutics Provides Update on its Clinical Trial Programs and Milestones
Interim Analyses for Key FOCUS Study Expected in August 2017 and September 2017 Investigator-Sponsor Pauses Enrollment in PAZOFOS Study in U.K. SOUTH SAN FRANCISCO, Calif. , June 12, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular
View HTML
Toggle Summary Mateon Therapeutics Receives FDA Fast Track Designation for OXi4503 in Patients with Acute Myeloid Leukemia
SOUTH SAN FRANCISCO, Calif. , June 07, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the U.S.
View HTML
Toggle Summary Mateon Provides Corporate Update and Reports First Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif. , May 08, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the
View HTML
Toggle Summary Mateon Therapeutics Announces Presentations at the Tumor Microenvironment Workshop
SOUTH SAN FRANCISCO, Calif. , April 27, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that four presentations regarding the company's
View HTML
Toggle Summary Mateon Announces Initiation of Investigator-Sponsored Phase 1 Study of CA4P in Combination with Everolimus in Neuroendocrine Tumors
SOUTH SAN FRANCISCO, Calif. , April 20, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the Markey Cancer Center at the University of
View HTML
Toggle Summary Mateon Therapeutics Announces Encouraging Results from First Interim Analysis of Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer
No Significant CA4P Drug Safety Issues Identified Initial Efficacy in Favor of CA4P, with 22% of CA4P Patients Responding versus 9% in the Control Arm Enrollment in the Study Continuing SOUTH SAN FRANCISCO, Calif. , April 18, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc.
View HTML